logo

For the Inventor, By the Inventor

Holland, PA, United States of America

Robert F Kaltenbach, Iii

This inventor holds 16 USPTO granted patents and 4 published patent applications and 1 EPO patent, primarily in LPA Antagonists. Top assignees: Bristol-Myers Squibb Compnay, Syngene International Limited, Other. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert F Kaltenbach, Iii. Retrieved from https://idiyas.com/inventor/robert-f-kaltenbach-iii

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 100.0


Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 81(Granted Patents)


Location History:

  • Holland, NJ (US) (2021)
  • Holland, PA (US) (2009 - 2023)

Company Filing History:

goldMedal15 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents
silverMedal1 out of 7 
 
Syngene International Limited
 patents
bronzeMedal1 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
LPA Antagonists
Cyclobutyl Acids
Triazole Carboxylic Acids
Isoxazole Compounds
Cyclopentyl Acids
Carbamoyl Cyclohexyl Acids
Met Kinase Inhibitors
Triazole Derivatives
Acid Chemistry
N-linked Compounds
O-linked Compounds
Cyclohexyl Acids
16 patents (USPTO):Explore Patents
1. 12466804 - Cyclobutyl carboxylic acids as LPA antagonists (2025-11-11),
2. 12435057 - Triazole carboxylic acids as LPA antagonists (2025-10-07),
3. 12384768 - Isoxazole carboxylic acids as LPA antagonists (2025-08-12),
4. 12209072 - Cyclopentyl acids as LPA antagonists (2025-01-28),
5. 12195444 - Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists (2025-01-14),
6. 11697646 - Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists (2023-07-11),
7. RE49352 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2023-01-02),
8. 11447475 - Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists (2022-09-20),
9. 11267800 - Cyclohexyl acid triazole azines as LPA antagonists (2022-03-08),
10. 11180488 - Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists (2021-11-23),
11. 11008300 - Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists (2021-05-18),
12. 11007180 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2021-05-18),
13. 10662172 - Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists (2020-05-26),
14. 10576062 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2020-03-03),
15. 10071078 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2018-09-11),

Title: Robert F Kaltenbach, III: Pioneering Inventor from Holland, PA

Introduction: Robert F Kaltenbach, III is a distinguished inventor hailing from Holland, PA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Robert F Kaltenbach, III holds several patents in various technological domains, including advancements in artificial intelligence, renewable energy, and medical devices.

Career Highlights: With a career spanning over two decades, Robert F Kaltenbach, III has worked with renowned tech companies, leading research institutions, and universities to develop cutting-edge solutions that have revolutionized the industry.

Collaborations: Throughout his career, Robert F Kaltenbach, III has collaborated with top inventors, patent attorneys, and research institutions worldwide, fostering a culture of innovation and excellence in all his projects.

Conclusion: Robert F Kaltenbach, III's relentless passion for innovation and his commitment to pushing the boundaries of technology make him a true pioneer in the world of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…